NFKBIA has the Capacity to Serve as a Diagnostic Biomarker for Prostate Cancer Patient

Abstract Background: Prostate cancer is the the second leading cause of cancer-related death in male. NF-κB inhibitor alpha gene (NFKBIA), is found dys-expressed in the progression of tumors. The aim of this study was to investigate the expression of NFKBIA and its diagnostic value in prostate cancer patients.Methods: The mRNA expression of NFKBIA was detected with quantitative real-time polymerase chain reaction (qRT-PCR) assay and the association of its expression with clinical characteristic was analyzed via Chi-square test. Receiver operating characteristic (ROC) curve was built to evaluate the diagnostic value of serum NFKBIA.Results: The mRNA expression level of NFKBIA was significantly increased in prostate cancer patients compared with healthy controls (P<0.01). The high expression of NFKBIA was significantly associated with pathological T stage (P=0.010) and differentiation (P=0.019). ROC curve showed that serum NFKBIA had a high diagnostic value in differentiating prostate cancer patients from healthy individuals. The area under the ROC curve (AUC) value was 0.873 corresponding with a sensitivity of 85.6% and a specificity of 78.3%.Conclusions: The expression of NFKBIA was up-regulated in serum of prostate cancer patients and it may be a useful diagnostic bio-maker for the early detection of this cancer.